120 related articles for article (PubMed ID: 34520614)
21. Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors.
Carrieri P; Carrat F; Di Beo V; Bourlière M; Barré T; De Ledinghen V; Pageaux GP; Bureau M; Cagnot C; Dorival C; Delarocque-Astagneau E; Marcellin F; Pol S; Fontaine H; Protopopescu C;
JHEP Rep; 2022 Jun; 4(6):100481. PubMed ID: 35514789
[TBL] [Abstract][Full Text] [Related]
22. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
23. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
Vallet-Pichard A; Correas JM; Dorival C; Zoulim F; Tran A; Bourlière M; Calès P; Guyader D; Bronowicki JP; Larrey D; Hezode C; Loustaud-Ratti V; Gournay J; de Ledinghen V; Asselah T; Ganne N; Metivier S; Chazouillères O; Leroy V; Rosa I; Samuel D; Mathurin P; Cagnot C; Fontaine H; Carrat F; Pol S;
Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101459. PubMed ID: 32595103
[TBL] [Abstract][Full Text] [Related]
24. The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C.
van Santen DK; Agius PA; Sasadeusz J; Fairley CK; Sievert W; Gane E; Iser D; O'Reilly M; Medland NA; Moore R; Hellard ME; Hoy JF; Doyle JS;
J Acquir Immune Defic Syndr; 2020 Dec; 85(5):e81-e89. PubMed ID: 32842055
[TBL] [Abstract][Full Text] [Related]
25. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
26. Treatment of hepatitis C: a systematic review.
Kohli A; Shaffer A; Sherman A; Kottilil S
JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
[TBL] [Abstract][Full Text] [Related]
27. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
28. [Hepatitis C in a psychiatric setting: A forgotten reservoir?].
Rolland B; Bailly F; Cutarella C; Drevon O; Carrieri P; Darque A; Hallouche N; Maptue N; Pol S; Llorca PM; Lang JP
Encephale; 2021 Apr; 47(2):181-184. PubMed ID: 32473777
[TBL] [Abstract][Full Text] [Related]
29. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
[TBL] [Abstract][Full Text] [Related]
30. Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection.
Feldman SF; Lapidus N; Dorival C; Diallo A; Amri I; Fontaine H; Pol S; Carrat F;
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):797-805. PubMed ID: 29749668
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.
Pageaux GP; Nzinga CL; Ganne N; Samuel D; Dorival C; Zoulim F; Cagnot C; Decaens T; Thabut D; Asselah T; Mathurin P; Habersetzer F; Bronowicki JP; Guyader D; Rosa I; Leroy V; Chazouilleres O; de Ledinghen V; Bourliere M; Causse X; Cales P; Metivier S; Loustaud-Ratti V; Riachi G; Alric L; Gelu-Simeon M; Minello A; Gournay J; Geist C; Tran A; Abergel A; Portal I; d'Alteroche L; Raffi F; Fontaine H; Carrat F; Pol S;
BMC Infect Dis; 2022 Jan; 22(1):94. PubMed ID: 35086481
[TBL] [Abstract][Full Text] [Related]
32. Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIV.
Bilal U; Lau B; Lazo M; McCaul ME; Hutton HE; Sulkowski MS; Moore RD; Chander G
AIDS Patient Care STDS; 2016 May; 30(5):200-7. PubMed ID: 27158847
[TBL] [Abstract][Full Text] [Related]
33. Risk of diabetes in HIV-infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort.
Provoost A; Dramé M; Cotte L; Cuzin L; Garraffo R; Rey D; Raffi F; Poizot-Martin I; Pugliese P; Bani-Sadr F;
Aliment Pharmacol Ther; 2018 Aug; 48(3):281-289. PubMed ID: 29901821
[TBL] [Abstract][Full Text] [Related]
34. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
[TBL] [Abstract][Full Text] [Related]
35. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
Barreiro P; Martín-Carbonero L; Núñez M; Rivas P; Morente A; Simarro N; Labarga P; González-Lahoz J; Soriano V
Clin Infect Dis; 2006 Apr; 42(7):1032-9. PubMed ID: 16511772
[TBL] [Abstract][Full Text] [Related]
36. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection.
Martinez MA; Franco S
Adv Exp Med Biol; 2021; 1322():139-157. PubMed ID: 34258740
[TBL] [Abstract][Full Text] [Related]
37. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
38. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
[TBL] [Abstract][Full Text] [Related]
39. Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort.
Knight R; Roux P; Vilotitch A; Marcellin F; Rosenthal E; Esterle L; Boué F; Rey D; Piroth L; Dominguez S; Sogni P; Salmon-Ceron D; Spire B; Carrieri MP;
Addiction; 2017 Sep; 112(9):1669-1679. PubMed ID: 28430385
[TBL] [Abstract][Full Text] [Related]
40. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
